TABLE 2.

Associations of serum albumin concentration with annual change in eGFRcys in HIV-infected WIHS participants.

	Unadjusted Estimate (95% CI)	P Value	Adjusted without ACR** Estimate (95% CI)	P Value	Adjusted with ACR** Estimate (95% CI)	P Value
Continuous Predictors
Serum Albumin, per −0.5 g/dL less	−0.44 (−0.59, −0.28)	<0.001	−0.56 (−0.72, −0.39)	<0.001	−0.55 (−0.71, −0.39)	<0.001
ACR, per doubling	−0.22 (−0.31, −0.14)	<0.001			−0.28 (−0.36, −0.20)	<0.001
Baseline eGFRcys, per 10- ml/min/1.73 m2 greater	−0.28 (−0.37, −0.20)	<0.001	−0.47 (−0.56, −0.39)	<0.001	−0.53 (−0.62, −0.45)	<.0001
Dichotomized Predictors
Serum Albumin < 3.8 g/dL	−0.43 (−0.74, −0.13)	0.005	−0.43 (−0.75, −0.12)	0.007	−0.42 (−0.73, −0.10)	0.009
ACR ≥ 30 mg/g	−0.50 (−0.96, −0.047)	0.03			−0.61 (−1.08, −0.15)	0.009
Baseline eGFRcys <60 ml/min/1.73 m2	1.15 (0.54, 1.76)	<0.001	1.53 (0.91, 2.1)	<0.001	1.73 (1.09, 2.4)	<0.001

ACR, albumin-creatinine ratio; CI, confidence interval; eGFR_cys, cystatin C–based estimated glomerular filtration rate; Women’s Interagency HIV Study (WIHS),

Note: Results reported as estimated annual change (95% confidence interval) in eGFRcys calculated from multivariable linear mixed models

^**Adjusted models control for age, race, HIV RNA, CD4, HCV, diabetes mellitus, anti-retroviral therapy use, baseline estimated glomerular filtration rate, systolic and diastolic blood pressures, body mass index, and study site. For ACR as a predictor instead of adjusting for ACR the full model adjusts for serum albumin concentration. Anti-retroviral therapy included current combination antiretroviral therapy use, current nucleoside reverse transcriptase inhibitor use, current non-nucleoside reverse transcriptase inhibitor use, and current protease inhibitor use.